MEK Inhibitors Market to Grow by Over $500 Million by 2030
The global market for MEK Inhibitors is predicted to experience substantial growth, increasing from US$995.1 million in 2023 to...
Omniscience and Inmune Bio Partner to Accelerate Alzheimer’s Drug Trial
OmniScience and INmune Bio have partnered to utilize OmniScience’s AI-powered platform, Vivo, in INmune Bio’s Phase 2 Alzheimer’s diseaseAlzheimer’s...
Next-Gen Cancer Diagnostics: ctDNA, CTC, miRNA Testing Drives Growth
The global Next Generation Cancer Diagnostics (NGCD) market is poised for significant expansion, projected to surge from US$16.6 billion...
Ajax Presents Phase 1 Trial Results for Myelofibrosis Treatment
Ajax Therapeutics, a biopharmaceutical company focused on developing advanced JAK inhibitors for myeloproliferative neoplasms (MPNs), will present data from...
Rallybio to Initiate RLYB116 Clinical PK/PD Study in 2025
Rallybio Corporation announced positive findings from new biomarker analyses and manufacturing process enhancements for RLYB116, its investigational once-weekly, subcutaneous...
PIF Partners Small Molecule SJIA Drug Granted FDA Rare Pediatric Disease Designation
PIF Partners’ investigational therapeutic, 101-PGC-005 (‘005), has received Rare Pediatric Disease Designation (RPDD) from the FDA for treating systemic...
Daiichi Sankyo’s Oncology Breakthroughs at ESMO Asia, SABCS & ASH
Daiichi Sankyo will present over 45 abstracts showcasing new clinical research in various cancers at the 2024 ESMO Asia...
Anzupgo® (Delgocitinib) Cream Approved in Great Britain
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved delgocitinib cream, a topical Janus kinase (JAK) inhibitor,...
Trio Pharmaceuticals Secures $3.1M to Advance Cancer Therapeutics
TRIO Pharmaceuticals, a biotechnology company developing bispecific antibodies for cancer treatment, secured $3.1 million in pre-Series A funding. This...
Kairos Pharma and City of Hope Team Up For Phase 2 Trial
Kairos Pharma (NYSE American: KAPA) is expanding its Phase 2 clinical trial for ENV105, a novel cancer drug resistance...